Abbvie Announces Updated Results From Phase 2 Epcore® Nhl-6 Study Evaluating The Potential For Outpatient Monitoring Of Epcoritamab In Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)
Sept 3 (Reuters) - Abbvie Inc ABBV.N:
ABBVIE ANNOUNCES UPDATED RESULTS FROM PHASE 2 EPCORE® NHL-6 STUDY EVALUATING THE POTENTIAL FOR OUTPATIENT MONITORING OF EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
ABBVIE INC - STUDY SHOWS CONSISTENT CRS AND ICANS INCIDENCE WITH PREVIOUS STUDIES
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Nebius Stock: Can This AI Infrastructure Play Really Double in 2026?

Intel Better-Than-Expected Earnings Released, Stock Surges 20% After-Hours, AI Computing Power Enters CPU Moment?

Semiconductor Sector Continues to Rise, Should Retail Investors Buy Intel or AMD?
Google Bets $40B on Anthropic: Is Google Cloud the New Growth Engine as Meta Challenges Ad Dominance?

Intel Posts Best Day Since 1987 as Nvidia Market Cap Reclaims $5 Trillion: Is the AI Trade Overstretched?

Tradingkey







